[Critical coronavirus disease 2019 caused by Delta variant: a case report with literature review].
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
; 34(5): 481-484, 2022 May.
Article
in Chinese
| MEDLINE | ID: covidwho-1903529
ABSTRACT
OBJECTIVE:
To investigate the curative efficacy and application value of convalescent plasma (CP) in severe and critical coronavirus disease 2019 (COVID-19) caused by Delta variant.METHODS:
The treatment process and results of CP therapy for a patient with critical COVID-19 caused by Delta variant were reported. The clinical application value of CP for COVID-19 caused by Delta variant was analyzed along with the literature review.RESULTS:
Our case was a 50-year-old male, who was imported from abroad and had not been vaccinated against COVID-19. The novel coronavirus nucleic acid test was negative before entry. On the second day after entry, fever occurred, novel coronavirus nucleic acid test was positive. Chest CT images showed bilateral multiple mottling and ground-glass opacity with symptoms of nausea, headache, loss of appetite, diarrhea, but no running nose, nasal obstruction, dyspnea, abnormal smell and taste. The infection rapidly developed from medium to critical. On the basis of standard treatment, Delta variant CP was intravenous dripped on the 10th day of hospital admission (the 6th day after becoming severe). The patient's condition improved rapidly.CONCLUSIONS:
The curative efficacy evaluation of this patient proved that CP therapy is of great value in the treatment of severe and critical COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Nucleic Acids
/
Coronavirus Infections
/
COVID-19
Type of study:
Case report
/
Diagnostic study
/
Experimental Studies
/
Prognostic study
/
Reviews
Topics:
Vaccines
/
Variants
Limits:
Humans
/
Male
/
Middle aged
Language:
Chinese
Journal:
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
Year:
2022
Document Type:
Article
Affiliation country:
Cma.j.cn121430-20220418-00382
Similar
MEDLINE
...
LILACS
LIS